These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22220636)

  • 1. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
    Zannad F; De Backer G; Graham I; Lorenz M; Mancia G; Morrow DA; Reiner Z; Koenig W; Dallongeville J; Macfadyen RJ; Ruilope LM; Wilhelmsen L;
    Fundam Clin Pharmacol; 2012 Apr; 26(2):163-74. PubMed ID: 22220636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal of trials for validation of 'risk-guided' cardiovascular disease prevention therapy.
    Castro A; Rosillo SO; Alonso A; Pedersen T
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):33-6. PubMed ID: 22801068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools.
    Marcovina SM; Crea F; Davignon J; Kaski JC; Koenig W; Landmesser U; Pieri PL; Schulz-Menger J; Shaw LJ; Sobesky J
    J Intern Med; 2007 Mar; 261(3):214-34. PubMed ID: 17305644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying novel biomarkers for cardiovascular disease risk prediction.
    Ge Y; Wang TJ
    J Intern Med; 2012 Nov; 272(5):430-9. PubMed ID: 22950687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging for prevention.
    Shaw LJ
    Med Clin North Am; 2012 Jan; 96(1):103-12. PubMed ID: 22391255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease risk assessment and prevention: current guidelines and limitations.
    Alagona P; Ahmad TA
    Med Clin North Am; 2015 Jul; 99(4):711-31. PubMed ID: 26042878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension.
    Ruilope LM; Segura J
    Clin Ther; 2005 Oct; 27(10):1658-68. PubMed ID: 16330303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management.
    Gupta M; Singh N; Tsigoulis M; Kajil M; Hirjikaka S; Quan A; Teoh H; Verma S
    Can J Cardiol; 2012; 28(1):14-9. PubMed ID: 22264843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to cardiovascular disease risk scoring and primary prevention in Europe.
    Hobbs FD; Jukema JW; Da Silva PM; McCormack T; Catapano AL
    QJM; 2010 Oct; 103(10):727-39. PubMed ID: 20685842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The PreFord Study. A prospective cohort study to evaluate the risk of a cardiovascular event (overall-collective) as well as a prospective, randomized, controlled, multicentre clinical intervention study (high-risk-collective) on primary prevention of cardiovascular diseases in the Ford Motor Company employees in Germany].
    Gysan DB; Latsch J; Bjarnason-Wehrens B; Albus C; Falkowski G; Herold G; Mey E; Heinzler R; Montiel G; Schneider CA; Stützer H; Türk S; Weisbrod M; Predel HG
    Z Kardiol; 2004 Feb; 93(2):131-6. PubMed ID: 14963679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis.
    Koenig W
    Ann Med; 2009; 41(5):332-43. PubMed ID: 19291518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
    Anderson JL
    Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
    Naghavi M; Falk E; Hecht HS; Jamieson MJ; Kaul S; Berman D; Fayad Z; Budoff MJ; Rumberger J; Naqvi TZ; Shaw LJ; Faergeman O; Cohn J; Bahr R; Koenig W; Demirovic J; Arking D; Herrera VL; Badimon J; Goldstein JA; Rudy Y; Airaksinen J; Schwartz RS; Riley WA; Mendes RA; Douglas P; Shah PK;
    Am J Cardiol; 2006 Jul; 98(2A):2H-15H. PubMed ID: 16843744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for treating lipids for prevention: risk stratification models with and without imaging.
    Okwuosa TM; Mallikethi-Reddy S; Jones DM
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):295-307. PubMed ID: 24840260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New biomarkers for cardiovascular risk evaluation].
    Chironi G
    Rev Prat; 2012 Jun; 62(6):783-5. PubMed ID: 22838270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.